10-Q: AIM ImmunoTech Reports Q1 2025 Results, Faces Delisting Concerns

Sentiment:

Quarterly Report 15 May 2025 4:45 PM

AIM ImmunoTech reports a decreased net loss for Q1 2025 but faces challenges including a potential delisting from NYSE American and going concern uncertainties.

Capital raiseThe company is exploring various funding sources, including a Universal Shelf Registration Statement and an At-The-Market Offering with Maxim.The company has an existing Equity Purchase Agreement with Atlas Sciences, LLC, which provides a potential source of funding.The company may seek to access the public equity market whenever conditions are favorable.

Worse than expectedThe company's revenue decreased year-over-year.The company's cash position decreased significantly.The company faces potential delisting from the NYSE American.

Summary

AIM ImmunoTech Inc. reported a net loss of $3.705 million for the three months ended March 31, 2025, compared to a net loss of $5.817 million for the same period in 2024.
The company's revenues were $16,000 for Q1 2025, down from $40,000 in Q1 2024.
Research and development expenses decreased to $1.080 million from $1.951 million year-over-year.
General and administrative expenses also decreased to $2.545 million from $3.815 million year-over-year.
As of March 31, 2025, AIM ImmunoTech had $2.247 million in cash, cash equivalents, and marketable investments, a decrease of $1.730 million from December 31, 2024.
The company faces potential delisting from the NYSE American due to non-compliance with continued listing requirements and has been suspended from NYSE American to OTC Markets.
AIM ImmunoTech is pursuing a reverse stock split, pending FINRA authorization, and is exploring various funding sources to address its liquidity concerns.
The company is focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, with a primary focus on Ampligen.
A forbearance agreement was entered into with Streeterville Capital, LLC, with a forbearance fee added to the outstanding balance of the note, resulting in an outstanding balance of $2,483,861.60.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has reduced its net loss and is pursuing strategies to address its financial challenges, it faces significant risks, including potential delisting and going concern uncertainties. The overall sentiment is cautiously negative.

Positives

The company's net loss decreased significantly, indicating improved cost management.
Research and development expenses were reduced, potentially reflecting increased efficiency or strategic prioritization.
General and administrative expenses were also reduced, contributing to the overall decrease in net loss.
The company is actively pursuing a reverse stock split to address listing compliance issues.
A forbearance agreement was reached with Streeterville Capital, LLC, providing temporary relief from certain defaults.

Negatives

The company's revenues decreased, indicating challenges in generating income from its products or services.
Cash, cash equivalents, and marketable investments decreased, raising concerns about the company's liquidity.
The company faces potential delisting from the NYSE American, which could negatively impact investor confidence and access to capital.
The company has a working capital deficit, indicating short-term financial challenges.
The company's stockholders equity was below the minimum requirements for continued listing on the NYSE American.

Risks

The company's ability to continue as a going concern is uncertain, raising concerns about its long-term viability.
The company's reliance on financing activities to fund operations poses a risk if it cannot secure additional funding.
Potential delisting from the NYSE American could negatively impact the company's stock price and investor confidence.
The company's dependence on the success of Ampligen and Alferon N Injection poses a risk if these products do not achieve commercial success.
The company's operations in Argentina are subject to economic risks, including hyper-inflation and currency devaluation.

Future Outlook

The company intends to continue its research and development efforts, focusing on Ampligen and Alferon N Injection, and is seeking additional funding to support its operations and clinical trials. The company is also working to regain compliance with NYSE American listing requirements.

Industry Context

AIM ImmunoTech operates in the immuno-pharma industry, which is characterized by high research and development costs, regulatory hurdles, and competition from larger pharmaceutical companies. The company's focus on Ampligen, a TLR3 agonist, positions it in the immuno-oncology and antiviral space, where there is significant unmet medical need and potential for growth.

Comparison to Industry Standards

It's difficult to directly compare AIM ImmunoTech's results to industry standards due to its unique product focus and stage of development.
Comparable companies in the immuno-oncology space include firms like BioNTech, Moderna, and Gritstone Bio, which are developing novel therapies for cancer and infectious diseases.
However, these companies often have significantly larger market capitalizations and more advanced clinical programs.
AIM ImmunoTech's reliance on external funding and its current financial challenges are not uncommon for small biotech companies in the early stages of development.
The company's success will depend on its ability to secure additional funding, advance its clinical programs, and ultimately commercialize its products.

Stakeholder Impact

Shareholders face the risk of further dilution and potential loss of investment if the company cannot secure additional funding or regain compliance with listing requirements.
Employees face uncertainty about the company's long-term viability and potential job security.
Customers and patients may experience delays or disruptions in access to the company's products and therapies.
Suppliers and creditors face the risk of non-payment if the company's financial condition deteriorates.

Next Steps

The company needs to regain compliance with NYSE American listing requirements.
The company needs to secure additional funding to support its operations and clinical trials.
The company needs to advance its clinical programs and seek regulatory approvals for its products.
The company needs to explore potential partnerships and licensing agreements to expand its reach and commercialize its products.

Key Dates

Date	Description
2017-01-01	Company entered into an agreement with Jubilant HollisterStier to manufacture batches of Ampligen.
2018-09-12	2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the 2018 Equity Incentive Plan) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.
2019-09-27	Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the Offering) of (i) 1,740,550 shares of common stock; (ii) pre-funded warrants exercisable for 7,148,310 shares of common stock (the Pre-funded Warrants), and (iii) warrants to purchase up to an aggregate of 8,888,860 shares of common stock (the Warrants).
2020-07-07	The Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to an aggregate of $ 500,000 worth of shares at the market price (including subsequent plans, the Employee Stock Purchase Plan).
2023-04-19	Company entered into an Equity Distribution Agreement (the EDA), with Maxim, pursuant to which we may sell from time to time, shares of our common stock having an aggregate offering price of up to $ 8.5 million through Maxim, as agent.
2024-02-16	Company entered into a Note and Note Purchase Agreement with Streeterville Capital LLC (Streeterville or the Lender).
2024-03-28	Company entered into a purchase agreement and a registration rights agreement with Atlas Sciences, LLC (Atlas), pursuant to which Atlas committed to purchase up to $ 15 million of common stock of the Company for a period of 24 months from the date of the purchase agreement.
2024-04-04	Company received a delisting letter from the NYSE American and trading in its common stock on the NYSE American was suspended.
2024-06-03	Company entered into a Securities Purchase Agreement (the Purchase Agreement) to complete an offering (the Transactions) with a single accredited investor (the Purchaser).
2025-02-26	The NYSE American accepted the Plan on February 26, 2025.
2025-03-31	End of the quarterly period.
2025-04-01	Company entered into a new EDA with Maxim pursuant to which it may issue and sell up to an aggregate of $ 3,000,000 shares of the Companys common stock from time to time through Maxim acting as agent.
2025-04-30	Company held a special meeting of stockholders to approve a series of alternate amendments to its Certificate of Incorporation to effect, at the option of its Board of Directors, a reverse stock split of its outstanding common stock at a ratio in the range of up to 1-for-100.
2025-05-13	Date of the report and date the Lender and the Borrower entered into a Forbearance Agreement.
2026-06-11	Deadline for the Company to regain compliance with NYSE American listing requirements.

Keywords

AIM ImmunoTech, Ampligen, Alferon N Injection, Financial Results, Delisting, Reverse Stock Split, Forbearance Agreement, Going Concern, Clinical Trials, Research and Development

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.